Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto)
网页Lutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic medicine for advanced metastatic prostate cancer. It’s a type of radiation that specifically targets a molecule on the surface of prostate cancer cells called PSMA.
Lutetium 177 - an overview | ScienceDirect Topics
网页Lutetium-177 (177 Lu) is a medium-energy β-emitter (E max of 498.3 keV) and low-energy gamma emitter (Eγ max of 208 keV), which decays with a half-life of approximately 6.6 days [74]. The first paper describing 177 Lu as a potential diagnostic agent was published in 1968 for skeletal imaging purposes [75].
Lutetium (177Lu) oxodotreotide - Wikipedia
网页Lutetium (177Lu) oxodotreotide (INN) or 177Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5]
Lutetium-177 shows significant rPFS benefit for ... - Mayo Clinic
网页Mayo Clinic researchers found that lutetium-177 (177 Lu)-PSMA-617 prolonged radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who were taxane-naive and had progressive disease after receiving androgen receptor pathway inhibition (ARPI) …
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate ...
网页2021年6月23日 · Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177 Lu)–PSMA-617 is a radioligand therapy that delivers...
Neuroendocrine Tumor Lu-177-Dotatate Therapy - StatPearls - NCBI Bookshelf
网页2024年2月12日 · Lutetium-177 (177 Lu)-dotatate therapy or peptide receptor radioligand therapy (PRRT) is indicated for treating gastroenteropancreatic neuroendocrine tumors and NET of the prostate gland. The FDA approved 177 Lu-dotatate therapy in 2018 to treat somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
A review of advances in the last decade on targeted cancer …
网页2021年12月15日 · The present review chronicles the advancement in the last decade in 177 Lu-radiopharmacy with a focus on 177 Lu produced via direct 176 Lu (n, γ) 177 Lu nuclear reaction in medium flux research reactors.
177
网页Background: [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177 Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant ...
177
网页6 天之前 · Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177 Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177 Lu-PSMA-617 cycles was 6·0 (IQR 4·0–6·0). Of patients assigned to ARPI change, 134 (57% ...
177 Lu放射性治疗药物研究新进展
网页摘要: 分别具有β-、 α、俄歇电子以及内转换电子衰变的放射性核素，在放射性药物研发以及临床评估中得到广泛应用，其中 177 Lu放射性治疗药物的研究在近年来得到了迅猛的发展，文献报道数量持续增长， 177 Lu放射性治疗药物引发了放药研究领域的强烈关注。
跳至内容